|
US7731947B2
(en)
|
2003-11-17 |
2010-06-08 |
Intarcia Therapeutics, Inc. |
Composition and dosage form comprising an interferon particle formulation and suspending vehicle
|
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
|
CA2913805A1
(en)
|
2005-11-07 |
2007-05-18 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting physiological solubility and stability
|
|
EP2359808B1
(en)
|
2006-08-09 |
2013-05-22 |
Intarcia Therapeutics, Inc |
Osmotic delivery systems and piston assemblies
|
|
CA2677932A1
(en)
|
2007-02-15 |
2008-08-21 |
Indiana University Research And Technology Corporation |
Glucagon/glp-1 receptor co-agonists
|
|
WO2008133908A2
(en)
|
2007-04-23 |
2008-11-06 |
Intarcia Therapeutics, Inc. |
Suspension formulations of insulinotropic peptides and uses thereof
|
|
MX2010004298A
(es)
|
2007-10-30 |
2010-05-03 |
Univ Indiana Res & Tech Corp |
Compuestos que exhiben actividad antagonista de glucagon y agonista de glp-1.
|
|
ES2509883T3
(es)
|
2007-10-30 |
2014-10-20 |
Indiana University Research And Technology Corporation |
Antagonistas de glucagón
|
|
CA2726861C
(en)
|
2008-02-13 |
2014-05-27 |
Intarcia Therapeutics, Inc. |
Devices, formulations, and methods for delivery of multiple beneficial agents
|
|
CN102105159B
(zh)
|
2008-06-17 |
2015-07-08 |
印第安纳大学研究及科技有限公司 |
基于gip的混合激动剂用于治疗代谢紊乱和肥胖症
|
|
PE20120332A1
(es)
|
2008-12-19 |
2012-04-14 |
Univ Indiana Res & Tech Corp |
Profarmacos de peptido de la superfamilia de glucagon basado en amida
|
|
EP2443146B1
(en)
|
2009-06-16 |
2016-10-05 |
Indiana University Research And Technology Corporation |
Gip receptor-active glucagon compounds
|
|
US9663778B2
(en)
|
2009-07-09 |
2017-05-30 |
OPKO Biologies Ltd. |
Long-acting coagulation factors and methods of producing same
|
|
RU2547990C2
(ru)
|
2009-09-28 |
2015-04-10 |
Интарсия Терапьютикс, Инк. |
Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
|
|
JO2976B1
(en)
*
|
2009-12-22 |
2016-03-15 |
ايلي ليلي اند كومباني |
Axentomodulin polypeptide
|
|
KR20120123443A
(ko)
|
2010-01-27 |
2012-11-08 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트
|
|
MX2012013001A
(es)
|
2010-05-13 |
2013-02-26 |
Univ Indiana Res & Tech Corp |
Peptidos de la superfamilia de glucagon que presentan actividad del receptor nuclear de hormonas.
|
|
JP6050746B2
(ja)
|
2010-05-13 |
2016-12-21 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation |
Ｇタンパク質共役受容体活性を示すグルカゴンスーパーファミリーのペプチド
|
|
US8507428B2
(en)
|
2010-12-22 |
2013-08-13 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting GIP receptor activity
|
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
|
US10166295B2
(en)
|
2011-06-02 |
2019-01-01 |
Opko Biologics Ltd. |
Pegylated OXM variants
|
|
KR102092206B1
(ko)
*
|
2011-06-02 |
2020-03-24 |
옵코 바이오로직스 리미티드 |
장기-작용성 glp-1/글루카곤 수용체 작용제
|
|
UA126465C2
(uk)
|
2011-06-10 |
2022-10-12 |
Ханмі Сайенс Ко., Лтд. |
Пептид, що має активність оксинтомодуліну, та фармацевтична композиція для лікування ожиріння, яка його містить
|
|
RU2607365C2
(ru)
|
2011-06-17 |
2017-01-10 |
Ханми Сайенс Ко., Лтд. |
Конъюгат, содержащий оксинтомодулин и фрагмент иммуноглобулина, и его применение
|
|
KR20140043793A
(ko)
|
2011-06-22 |
2014-04-10 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
글루카곤/glp-1 수용체 공동-작용물질
|
|
RS56173B1
(sr)
|
2011-06-22 |
2017-11-30 |
Univ Indiana Res & Tech Corp |
Koagonisti receptora za glukagon/glp-1 receptora
|
|
JP6324315B2
(ja)
|
2011-11-17 |
2018-05-16 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ |
グルココルチコイド受容体の活性を示すグルカゴンスーパーファミリーのペプチド
|
|
HK1207564A1
(en)
*
|
2012-04-19 |
2016-02-05 |
Opko Biologics Ltd |
Long-acting oxyntomodulin variants and methods of producing same
|
|
EA201492269A1
(ru)
|
2012-06-04 |
2016-02-29 |
Опко Байолоджикс Лтд. |
Пегилированные варианты oxm
|
|
CN104583232B
(zh)
|
2012-06-21 |
2018-04-13 |
印第安纳大学研究及科技有限公司 |
展现gip受体活性的胰高血糖素类似物
|
|
KR101968344B1
(ko)
|
2012-07-25 |
2019-04-12 |
한미약품 주식회사 |
옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
|
|
AR092873A1
(es)
|
2012-09-26 |
2015-05-06 |
Cadila Healthcare Ltd |
Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
|
|
UA116217C2
(uk)
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
|
KR101993393B1
(ko)
|
2012-11-06 |
2019-10-01 |
한미약품 주식회사 |
옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
|
|
WO2014073842A1
(en)
|
2012-11-06 |
2014-05-15 |
Hanmi Pharm. Co., Ltd. |
Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
|
|
AU2013366692B2
(en)
|
2012-12-21 |
2017-11-23 |
Sanofi |
Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
|
|
EP2961765A4
(en)
*
|
2013-03-15 |
2016-11-09 |
Adaerata Ltd Partnership |
SMALL MOLECULAR PCSK9 MODULATORS AND METHOD OF USE THEREOF
|
|
US20150158926A1
(en)
|
2013-10-21 |
2015-06-11 |
Opko Biologics, Ltd. |
Long-acting polypeptides and methods of producing and administering same
|
|
EP3080152A1
(en)
|
2013-12-13 |
2016-10-19 |
Sanofi |
Non-acylated exendin-4 peptide analogues
|
|
WO2015086728A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
|
|
WO2015086733A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Dual glp-1/glucagon receptor agonists
|
|
EP3080154B1
(en)
|
2013-12-13 |
2018-02-07 |
Sanofi |
Dual glp-1/gip receptor agonists
|
|
TW201625670A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
|
|
TW201625669A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
|
|
TW201625668A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
|
|
US9932381B2
(en)
|
2014-06-18 |
2018-04-03 |
Sanofi |
Exendin-4 derivatives as selective glucagon receptor agonists
|
|
TWI802396B
(zh)
|
2014-09-16 |
2023-05-11 |
南韓商韓美藥品股份有限公司 |
長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
|
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
|
EP3230309B1
(en)
|
2014-12-10 |
2023-03-29 |
OPKO Biologics Ltd. |
Methods of producing long acting ctp-modified growth hormone polypeptides
|
|
KR102418477B1
(ko)
|
2014-12-30 |
2022-07-08 |
한미약품 주식회사 |
글루카곤 유도체
|
|
RU2730996C2
(ru)
|
2015-06-03 |
2020-08-26 |
Интарсия Терапьютикс, Инк. |
Системы установки и извлечения имплантата
|
|
AR105319A1
(es)
|
2015-06-05 |
2017-09-27 |
Sanofi Sa |
Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
|
|
WO2016198624A1
(en)
|
2015-06-12 |
2016-12-15 |
Sanofi |
Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
|
|
WO2016198628A1
(en)
|
2015-06-12 |
2016-12-15 |
Sanofi |
Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
|
|
TW201706291A
(zh)
|
2015-07-10 |
2017-02-16 |
賽諾菲公司 |
作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
|
|
TWI622596B
(zh)
|
2015-10-26 |
2018-05-01 |
美國禮來大藥廠 |
升糖素受體促效劑
|
|
KR102574993B1
(ko)
|
2016-05-16 |
2023-09-06 |
인타르시아 세라퓨틱스 인코포레이티드 |
글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
|
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
|
MY206271A
(en)
|
2016-07-11 |
2024-12-06 |
Opko Biologics Ltd |
Long-acting coagulation factor vii and methods of producing same
|
|
TW201832783A
(zh)
|
2016-12-02 |
2018-09-16 |
法商賽諾菲公司 |
包含ｇｌｐ－１／胰高血糖素雙重激動劑、連接子和透明質酸的接合物
|
|
JP7286542B2
(ja)
|
2017-01-03 |
2023-06-05 |
インターシア セラピューティクス，インコーポレイティド |
Ｇｌｐ－１受容体アゴニストの持続的投与及び薬物の同時投与を含む方法
|
|
CN108299554B
(zh)
*
|
2017-01-13 |
2021-05-25 |
博瑞生物医药（苏州）股份有限公司 |
胃泌酸调节素类似物
|
|
CN106986924A
(zh)
*
|
2017-03-23 |
2017-07-28 |
中国药科大学 |
胃泌酸调节素（oxm）类似物及其应用
|
|
US12441776B2
(en)
|
2018-11-30 |
2025-10-14 |
Eirgen Pharma Ltd. |
Oxyntomodulin peptide analog formulations
|
|
KR102154959B1
(ko)
*
|
2020-04-29 |
2020-09-10 |
동아에스티 주식회사 |
지속형 glp-1 및 글루카곤 수용체 이중작용제
|
|
WO2025169190A2
(en)
|
2024-02-06 |
2025-08-14 |
Opko Biologics Ltd. |
Modified oxyntomodulin and methods of use thereof
|